Generic placeholder image

Current Drug Targets - Immune, Endocrine & Metabolic Disorders


ISSN (Print): 1568-0088
ISSN (Online): 1875-5917

DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus

Author(s): Angela Subauste and Charles F. Burant

Volume 3, Issue 4, 2003

Page: [263 - 270] Pages: 8

DOI: 10.2174/1568005310303040263

Price: $65


Obesity is currently an exceptionally common problem in humans. The last several years have produced a significant number of breakthroughs in obesity related areas of investigation. Triglycerides are considered the main form of storage of excess calories in fat. A key enzyme in the synthesis of triglycerides is acylCoA: diacylglycerol acyltransferase (DGAT). Recent studies have shown that mice deficient in this enzyme are resistant to diet induced obesity and have increased insulin and leptin sensitivity. These effects suggest that inhibition of DGAT in vivo may be a novel therapeutic target not only for obesity but also for diabetes.

Keywords: dgat, obesity, type 2 diabetes mellitus, acylcoa: diacylglycerol, acyltransferase, free fatty acids

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy